Skip to content

Hyperbaric Novabupi® in Spinal Anesthesia in Lower Limbs Vascular Surgery

Non-inferiority Study of Hyperbaric Novabupi® (Bupivacaine S75: R25) Compared to Hyperbaric Neocaine® (Bupivacaine S50: R50) in Spinal Anesthesia in Lower Limbs Vascular Surgery

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03883763
Enrollment
120
Registered
2019-03-21
Start date
2022-04-01
Completion date
2023-11-30
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Anesthesia, Vascular Surgery

Brief summary

This is a multicenter, randomized, double-blind, active-controlled study to evaluate the non-inferiority of hyperbaric Novabupi® versus hyperbaric Neocaine® in spinal anesthesia in lower limbs vascular surgery. The schedule consists of four visits: screening (visit 1); pre-anesthetic evaluation and randomization (visit 2); treatment (visit 3) and discharge from study (visit 4).

Interventions

DRUGbupivacaine S75:R25 plus 8% glucose

Spinal anesthesia, 20 mg

DRUGbupivacaine S50:R50 plus 8% glucose

Spinal anesthesia, 20 mg

Sponsors

Cristália Produtos Químicos Farmacêuticos Ltda.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Provision of written informed consent * Both sexes * Age between 18 and 80 years, inclusive * ASA category I or II * Indication of spinal anesthesia for varicose vein surgery in lower limbs with a maximum duration of 3 hours.

Exclusion criteria

* Contraindications to spinal anesthesia * Hypersensitivity or intolerance to local anesthetics or to the components of formula * Use of any anticoagulant, regardless of type until 60 days before entering the study * Spinal cord injuries, peripheral neuropathies or any other neurological conditions leading to sensory and / or motor disorders * Dementia, mental retardation and other major cognitive changes * Obesity with body mass index (BMI) \> 30 or difficulty in performing the puncture * Anatomical difficulty in the spine in the opinion of the Investigator that can make puncture difficult * Any previous surgical intervention of the spine * Tattoo at the puncture site * Participants with a history of alcohol or illicit drug abuse, as defined by Diagnostic and Statistical Manual of Mental Disorders, 5th edition * Pernicious anemia * History of severe anaphylactic reactions or Steven-Johnson disease * Changes in safety exams (applicable at the time of randomization): * International Normalized Ratio ≥ 1.4 * Hemoglobin \< 10 g / dL * Platelet count \<100,000 / mm3 * Glycemia\> 200 mg / dL * Bradyarrhythmias: heart block with clinical repercussion in the investigator's opinion * Maximum of eight ventricular extrasystoles per minute, evident on the ECG * Pregnancy or lactation * Any other condition that, in the opinion of the Investigator, may lead to an increased risk for the participant.

Design outcomes

Primary

MeasureTime frameDescription
Comparison between arms from latency to T10 dermatome sensitive block20 minutesTime elapsed between the withdrawal of the needle at the end of the injection of the local anesthetic and the absence of response to sensorial stimuli in the region corresponding to the T10 dermatome
Comparison between arms from the duration of the sensory block24 hoursTime elapsed between the withdrawal of the needle at the end of the local anesthetic injection and the presence of positive sensitivity by needle stimulation in the L5 dermatome

Secondary

MeasureTime frameDescription
Comparison between arms from the highest level of sensory block3 hours
Comparison between arms from the time to reach the highest level of sensory block1 hour
Comparison between arms from the time for the 4-segment regression of the sensory block3 hoursThe height of the sensitive block will be evaluated every 5 minutes until the maximum level is reached. From this point, the height of the block will be evaluated every 10 minutes until the regression of 4 levels
Comparison between arms from the degree of motor blockage when blocking T10 sensitive20 minutesThe motor block will be evaluated by the modified Bromage scale. The degree of motor block will be assessed when the sensory block reaches T10. The motor block will be evaluated every 5 minutes from the end of the anesthetic injection (time 0) through the modified Bromage scale: * 0 = without motor block, * 1 = blocked hip, * 2 = blocked hip and knee, * 3 = blocked hip, knee and ankle. Will be recorded: * the degree of motor blockage when the sensory block reaches T10, * the time to reach the maximum block, * time for full recovery (Bromage score 0).
Comparison between arms of cardiovascular safety24 hoursEvidenced by the incidence, severity and causality of clinically significant changes in blood pressure measured automatically by cardiac monitoring. Every 5 minutes blood pressure will be recorded until completing 60 minutes, every 10 minutes until completing 120 minutes, every 20 minutes until completing 180 minutes and every 30 minutes until complete recovery of the motor function.
Comparison between arms from the percentage of motor and sensory block failure20 minutesAfter the needle has been withdrawn, the anesthetic should be installed for up to 20 minutes. If no sensory and / or motor blockage is observed after this period, the Investigator will indicate that there was an anesthetic failure that should be classified as: A. total block failure (absence of anesthesia in sensory and motor aspects with preserved sensitivity of the perineal region) B. partial failure (when any area below the T10 dermatome shows signs of analgesia or motor block, but surgery can not be performed, requiring intense sedation or general anesthesia). In case of failure, the participant will be immediately discontinued from the study and the surgery will normally proceed with anesthetic procedure at the discretion of the Investigator. Anesthesia failure should be reported as an adverse event.
Comparison between arms from the occurrence of adverse events7 daysAdverse event information will be collected from all participants on all visits
Comparison between arms of respiratory and cardiovascular safety12 hoursEvidenced by the incidence, severity and causality of clinically significant SpO2 changes. Every 5 minutes SpO2 will be recorded until completing 60 minutes, every 10 minutes until completing 120 minutes, every 20 minutes until 12 hours.
Comparison between arms from the duration of the motor block24 hoursDuration of motor block will be considered as the time interval between needle withdrawal after puncture and return to score 0 on the modified Bromage scale. Time will be recorded to reach grade 3 motor block and at the end of surgery. During anesthesia recovery, evaluations will be performed every 15 minutes

Countries

Brazil

Contacts

Primary ContactJoão B Garcia, MD/PhD
jbgarcia@uol.com.br+559888020622
Backup ContactJuliana S Mussalem, PhD
juliana.mussalem@cristalia.com.br+551137236483

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026